BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30277666)

  • 1. Studies on selected molecular factors in endometrial cancers.
    Markowska A; Szarszewska M; Żurawski J; Sajdak S; Knapp P; Gryboś A; Olejek A; Bednarek W; Roszak A; Jóźwik M; Marszałek A; Filas V; Wójcik-Krowiranda K; Mądry R; Markowska J; Sozański R
    Adv Clin Exp Med; 2018 Oct; 27(10):1417-1424. PubMed ID: 30277666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 3. Culture characters, genetic background, estrogen/progesterone receptor expression, and tumorigenic activities of frequently used sixteen endometrial cancer cell lines.
    Qu W; Zhao Y; Wang X; Qi Y; Zhou C; Hua Y; Hou J; Jiang SW
    Clin Chim Acta; 2019 Feb; 489():225-232. PubMed ID: 30107158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Modifiers of Hormone Receptor Action: Decreased Androgen Receptor Expression in Mismatch Repair Deficient Endometrial Endometrioid Adenocarcinoma.
    Gan Q; Crumley S; Broaddus RR
    Int J Gynecol Pathol; 2019 Jan; 38(1):44-51. PubMed ID: 29210800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathology of Endometrial Carcinoma.
    Lax SF
    Adv Exp Med Biol; 2017; 943():75-96. PubMed ID: 27910065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of nesfatin and selected molecular factors in various types of endometrial cancer.
    Markowska A; Szarszewska M; Knapp P; Grybos A; Grybos M; Marszalek A; Filas V; Wojcik-Krowiranda K; Swornik M; Markowska J
    Ginekol Pol; 2019; 90(10):571-576. PubMed ID: 31686413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.
    Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D
    Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
    Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
    Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
    Lax SF
    Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
    Chapel DB; Yamada SD; Cowan M; Lastra RR
    Gynecol Oncol; 2018 Jun; 149(3):570-574. PubMed ID: 29656794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
    Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
    PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
    Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
    Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of estrogen and progesterone receptors isoforms in endometrial cancer.
    Kreizman-Shefer H; Pricop J; Goldman S; Elmalah I; Shalev E
    Diagn Pathol; 2014 Mar; 9():77. PubMed ID: 24684970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MLH1 and MSH2 protein expression as a pre-screening marker in hereditary and non-hereditary endometrial hyperplasia and cancer.
    Berends MJ; Hollema H; Wu Y; van Der Sluis T; Mensink RG; ten Hoor KA; Sijmons RH; de Vries EG; Pras E; Mourits MJ; Hofstra RM; Buys CH; Kleibeuker JH; van Der Zee AG
    Int J Cancer; 2001 May; 92(3):398-403. PubMed ID: 11291077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of body mass index with ER, PR and 14-3-3σ expression in tumor and stroma of type I and type II endometrial carcinoma.
    Peevey JF; Seagle BL; Maniar KP; Kim JJ
    Oncotarget; 2017 Jun; 8(26):42548-42559. PubMed ID: 28476021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unusual Mismatch Repair Immunohistochemical Patterns in Endometrial Carcinoma.
    Watkins JC; Nucci MR; Ritterhouse LL; Howitt BE; Sholl LM
    Am J Surg Pathol; 2016 Jul; 40(7):909-16. PubMed ID: 27186853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
    Köbel M; Atenafu EG; Rambau PF; Ferguson SE; Nelson GS; Ho TC; Panzarella T; McAlpine JN; Gilks CB; Clarke BA; Bernardini MQ
    Gynecol Oncol; 2016 Jun; 141(3):559-563. PubMed ID: 27072807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of MMR in endometrial adenocarcinoma in women under 50 years old].
    Wu HX; Song JC; Shi YQ; Liu YX
    Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):733-6. PubMed ID: 23302332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.